EBV-Related Post-Transplant Lymphoproliferative Disorder

Clinical trial pipeline · Data from ClinicalTrials.gov

See which EBV-Related Post-Transplant Lymphoproliferative Disorder trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 4 trials

RecruitingNot Applicable

NCT07488728

Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-A…

This study investigates the impact of letermovir prophylaxis on viral infections (including CMV, EBV, BKV, HHV-6/7, RSV, ADV, HSV, etc.) following allogeneic he…

China80 participantsStarted 2025-10-01

Treatment: Letermovir

RecruitingPhase 1/2

NCT07438067

EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell Transplantation

This exploratory clinical study focuses on the use of EBV-AST cell infusion for treating EBV-DNA viremia following allogeneic hematopoietic stem cell transplant…

China18 participantsStarted 2025-03-26

Treatment: EBV-AST cell

RecruitingPhase 1

NCT06672705

Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders

This phase Ib trial tests the safety and effectiveness of epcoritamab in treating patients with post-transplant lymphoproliferative disorder (PTLD) that has com…

United States26 participantsStarted 2025-06-16

Treatment: Biopsy, Biospecimen Collection

RecruitingNot Applicable

NCT05794880

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs)…

United States40 participantsStarted 2023-05-01

Treatment: Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)

All recent trials (49 shown)

SuspendedPhase 1

NCT06741072

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting…

This phase 1B trial tests the safety, side effects and best dose of rh-Hsc70- BZLF1 peptide complex (OSU-2131) with Stimulon (Trademark) QS-21 and evaluates how…

United States55 participantsStarted 2026-07-15

Treatment: Biospecimen Collection, Dulbecco''s Phosphate-Buffered Saline

CompletedPhase 2

NCT02900976

Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Tr…

This pilot phase II trial studies how well rituximab and latent membrane protein (LMP)-specific T-cells work in treating pediatric solid organ recipients with E…

United States18 participantsStarted 2017-03-22

Treatment: Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes, Rituximab

EBV-Related Post-Transplant Lymphoproliferative Disorder

Trial phase breakdown

Trial status

Actively recruiting — 4 trials

Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-A…

EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell Transplantation

Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

All recent trials (49 shown)

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting…

Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Tr…

Trial phase breakdown

Trial status

Actively recruiting — 4 trials

Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-A…

EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell Transplantation

Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

All recent trials (49 shown)

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting…

Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Tr…

Comparative Autoantibody and Immunologic Cell Marker Study

An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas

A Study of the Safety and Efficacy of EBV Specific T-cell Lines

Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant

Early Detection of Epstein-Barr Virus Related Disease.

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

Collecting and Storing Blood Samples From Patients With Cancer

Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial

Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body I…

Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppres…

Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer

Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer

Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem…

Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers